BioGaia AB: Interim report third quarter January – September 2022
THIRD QUARTER 2022 · Net sales amounted to SEK 257.7 million (173.8), an increase of SEK 83.9 million, or 48% (excluding foreign exchange effects, 33%) of which the acquisition of Nutraceutics accounted for an increase of SEK 20.8 million (12%). Organic growth was 21%. · Net sales in the Paediatrics segment amounted to SEK 205.7 million (130.8), an increase of 57% (excluding foreign exchange effects, 41%). · Net sales in the Adult Health segment amounted to SEK 50.5 million (42.1), an increase of 20% (excluding foreign exchange effects, 7%). · Operating expenses amounted to